General Biologicals Corporation

Executive Summary

General Biologicals Corporation (GBC) is a Taiwan-based contract development and manufacturing organization (CDMO) specializing in biologics, including monoclonal antibodies, recombinant proteins, and cell-based therapies. Founded in 2020, GBC leverages a proprietary high-throughput bioprocessing platform and GMP-certified facilities to offer end-to-end services from cell line development to commercial-scale production. The company focuses on oncology, immunology, and infectious disease therapeutics, targeting fast-growing Asian markets. With $120 million raised and a team of 200-500 employees, GBC is well-positioned to capture increasing demand for biologics manufacturing in the region. Its strategic location in Taipei provides access to a skilled workforce and proximity to key pharmaceutical hubs. GBC's platform technology aims to reduce production costs and timelines, making it an attractive partner for biotech and pharma companies seeking to outsource biologics manufacturing. The company's growth trajectory is supported by the expanding biopharmaceutical market in Asia and the global trend toward outsourcing complex biologics production.

Upcoming Catalysts (preview)

• Q3 2026New CDMO Contract with Major Pharma70% success
• Q4 2026Completion of New GMP Manufacturing Facility Expansion80% success
• Q2 2026Strategic Partnership for Cell Therapy Manufacturing60% success